As of 2026-10-12, the EV/EBITDA ratio of Sutro Biopharma Inc (STRO) is -2.56. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. STRO's latest enterprise value is 421.18 mil USD. STRO's TTM EBITDA according to its financial statements is -164.34 mil USD. Dividing these 2 quantities gives us the above STRO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.3x - 16.5x | 15.5x |
| Forward P/E multiples | 16.9x - 22.1x | 20.2x |
| Fair Price | (179.16) - (175.19) | (188.18) |
| Upside | -1355.5% - -1327.7% | -1418.7% |
| Date | EV/EBITDA |
| 2026-10-09 | -2.56 |
| 2026-10-08 | -2.67 |
| 2026-10-07 | -2.60 |
| 2026-10-06 | -2.58 |
| 2026-10-05 | -2.65 |
| 2026-10-02 | -2.67 |
| 2026-10-01 | -2.73 |
| 2026-09-30 | -2.75 |
| 2026-09-29 | -2.75 |
| 2026-09-28 | -2.74 |
| 2026-09-25 | -2.74 |
| 2026-09-24 | -2.71 |
| 2026-09-23 | -2.71 |
| 2026-09-22 | -2.75 |
| 2026-09-21 | -2.77 |
| 2026-09-18 | -2.67 |
| 2026-09-17 | -2.68 |
| 2026-09-16 | -2.70 |
| 2026-09-15 | -2.79 |
| 2026-09-14 | -2.83 |
| 2026-09-11 | -2.82 |
| 2026-09-10 | -2.92 |
| 2026-09-09 | -2.97 |
| 2026-09-08 | -3.05 |
| 2026-09-04 | -3.15 |
| 2026-09-03 | -3.20 |
| 2026-09-02 | -3.19 |
| 2026-09-01 | -3.22 |
| 2026-08-31 | -3.16 |
| 2026-08-28 | -3.19 |
| 2026-08-27 | -3.27 |
| 2026-08-26 | -3.28 |
| 2026-08-25 | -3.29 |
| 2026-08-24 | -3.19 |
| 2026-08-21 | -3.25 |
| 2026-08-20 | -3.26 |
| 2026-08-19 | -3.33 |
| 2026-08-18 | -3.35 |
| 2026-08-17 | -3.37 |
| 2026-08-14 | -3.19 |
| 2026-08-13 | -3.27 |
| 2026-08-12 | -3.27 |
| 2026-08-11 | -3.65 |
| 2026-08-10 | -3.70 |
| 2026-08-07 | -3.68 |
| 2026-08-06 | -3.56 |
| 2026-08-05 | -3.65 |
| 2026-08-04 | -3.71 |
| 2026-08-03 | -3.65 |
| 2026-07-31 | -3.56 |